Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by MirrorWorldManon Dec 13, 2021 6:54pm
175 Views
Post# 34227035

RE:RE:RE:Out of topic?

RE:RE:RE:Out of topic?The need to always generate operating cash from warrants is equally disturbing. as we see constantly see dilution and less shareholder value.  The market must cease to be the main rubber chicken source of cash for Howie. I have seen companies do this for years and eventually reach the limit to allowable shares outstanding.   A company must generate profit or it will fail. I knew the SGLT2 was lost but we need revenue forecasts for guidance. Silence is always bad
news for Howie. I remember another December a few years back when Howie announced the previous partner for 1067 walked away from the table.  The stock tanked to .08 etc etc.  What is the budgeted revenue for 2022 and can it meet operating expenses. Give us that Howie and stop being so damn incompetent 
<< Previous
Bullboard Posts
Next >>